**AstraZeneca Pharma India Limited**

**Regd. Office : Block N1, 12th Floor, Manyata Embassy Business Park, Rachenahalli, Outer Ring Road, Bangalore 560 045**

**Statement of unaudited financial results for the quarter ended 30 June 2022**

Rs in lakhs except for earnings per share data

| Sl No. | Particulars | 3 months ended 30/06/2022 | Previous 3 months ended 31/03/2022 | Corresponding 3 months ended in the previous year 30/06/2021 | Year ended 31/03/2022 |
|---|---|---|---|---|---|
| | | Unaudited | Refer note 4 | Unaudited | Audited |
| 1 | **Income** | | | | |
| | a) Revenue from operations | 23,233.20 | 23,196.33 | 17,540.20 | 80,560.01 |
| | b) Other income | 411.42 | 368.39 | 289.98 | 1,475.76 |
| | **Total income** | **23,644.62** | **23,564.72** | **17,830.18** | **82,035.77** |
| 2 | **Expenses** | | | | |
| | (a) Cost of materials consumed | 1,589.15 | 2,271.99 | 1,767.95 | 8,961.06 |
| | (b) Purchase of stock-in-trade | 7,531.44 | 6,176.56 | 3,305.88 | 20,788.07 |
| | (c) Changes in inventories of finished goods, work-in-progress and stock-in-trade | (782.80) | 307.31 | 1,572.98 | 1,447.01 |
| | (d) Employee benefit expense (Refer Note 3) | 6,837.12 | 5,848.31 | 5,479.34 | 23,020.62 |
| | (e) Depreciation expense | 459.18 | 440.69 | 476.08 | 1,694.89 |
| | (f) Allowance for expected credit loss (net) | 99.00 | 104.74 | 129.25 | 399.93 |
| | (g) Selling, marketing and distribution expense | 1,073.50 | 1,613.93 | 1,028.45 | 5,071.91 |
| | (h) Other expenses | 4,089.31 | 3,077.43 | 2,693.26 | 12,253.94 |
| | (i) Finance costs | 18.82 | 20.71 | 26.59 | 94.72 |
| | **Total expenses** | **20,914.72** | **19,861.67** | **16,479.78** | **73,732.15** |
| 3 | **Profit before tax (1-2)** | **2,729.90** | **3,703.05** | **1,350.40** | **8,303.62** |
| 4 | **Tax expense** | | | | |
| | - Current tax | 767.51 | 921.43 | 416.65 | 2,262.94 |
| | - Deferred tax credit | (52.87) | (16.71) | (90.58) | (118.60) |
| | **Total tax expense** | **714.64** | **904.72** | **326.07** | **2,144.34** |
| 5 | **Profit after tax (3-4)** | **2,015.26** | **2,798.33** | **1,024.33** | **6,159.28** |
| 6 | **Other comprehensive income/(loss)** | | | | |
| | A. Items that will not be reclassified to profit or loss | | | | |
| | Re-measurement gains/(losses) on post employment benefit obligations | (9.45) | (117.09) | (12.32) | (231.59) |
| | Income tax effect on above | 2.38 | 29.47 | 3.10 | 58.29 |
| | **Total other comprehensive income/ (loss), net of income tax** | **(7.07)** | **(87.62)** | **(9.22)** | **(173.30)** |
| | **Total comprehensive income for the period (5+6)** | **2,008.19** | **2,710.71** | **1,015.11** | **5,985.98** |
| 7 | **Paid-up equity share capital (Face value of Rs 2/- per equity share)** | **500.00** | **500.00** | **500.00** | **500.00** |
| 8 | **Reserves (excluding revaluation reserves as per balance sheet)** | - | - | - | 50,639.29 |
| 9 | **Earnings per equity share of Rs 2/- each (basic and diluted)** | **8.06** | **11.19** | **4.10** | **24.64** |

Price Waterhouse & Co Chartered Accountants LLP
LLPIN AAC-4362
FRN 304026E/E300009
Bengaluru

AstraZeneca Pharma India Limited
Bangalore

**AstraZeneca Pharma India Limited**
**Regd. Office : Block N1, 12th Floor, Manyata Embassy Business Park, Rachenahalli, Outer Ring Road, Bangalore 560 045**

**Statement of unaudited financial results for the quarter ended 30 June 2022**

Notes:

1 The financial results have been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (as amended) prescribed under Section 133 of the Companies Act, 2013 and other recognised accounting practices and policies to the extent applicable.

2 The Company has identified 'Healthcare Segment' as its only reportable segment in accordance with the requirements of Ind AS 108, 'Operating Segments'. Accordingly no segment information has been provided.

3 The employee benefit expense for the quarter ended 30 June 2022 includes one-time ex gratia of Rs.998.33 lakhs paid to certain resigned employees.

4 The figures for the quarter ended 31 March 2022 are the balancing figures between the audited figures in respect of the full financial year 31 March 2022 and the published unaudited year to date figures up to the third quarter of the respective financial year i.e., 31 December 2021 which were subjected to review by the statutory auditors.

5 Previous period's figures have been regrouped/reclassified, where necessary, to conform with the current period's presentation for the purpose of comparability.

6 This statement of financial results was reviewed and recommended by the Audit Committee of the Board and subsequently approved by the Board of Directors at their respective meetings held on 08 August 2022. The Statutory auditors of the Company have carried out a limited review of this statement of financial results for the quarter ended 30 June 2022.

By Order of the Board of Directors
For AstraZeneca Pharma India Limited

Place: Bengaluru
Date: 08 August, 2022

Gagandeep Singh Bedi
Managing Director

Price Waterhouse & Co Chartered Accountants LLP
LLPIN AAC-4362
FRN 304026E/E300009
Bengaluru